{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:23:16Z","timestamp":1793038996165,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41594-023-01041-4","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T12:01:51Z","timestamp":1690200111000},"page":"1160-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities"],"prefix":"10.1038","volume":"30","author":[{"given":"Yuxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Remillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugoma","family":"Onubogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7820-2567","authenticated-orcid":false,"given":"Barbara","family":"Karakyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Asiaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa R.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-6154","authenticated-orcid":false,"given":"Kirsten","family":"Bowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige A.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-9847","authenticated-orcid":false,"given":"Adam D.","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-7241","authenticated-orcid":false,"given":"Christopher J.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-5146","authenticated-orcid":false,"given":"Michalina","family":"Janiszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Cravatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-3481","authenticated-orcid":false,"given":"Michael A.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"1041_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrc.2016.148","volume":"17","author":"J Shortt","year":"2017","unstructured":"Shortt, J., Ott, C. J., Johnstone, R. W. & Bradner, J. E. A chemical probe toolbox for dissecting the cancer epigenome. Nat. Rev. Cancer 17, 160\u2013183 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1041_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2020.12.008","volume":"39","author":"L Chang","year":"2021","unstructured":"Chang, L., Ruiz, P., Ito, T. & Sellers, W. R. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell. 39, 466\u2013479 (2021).","journal-title":"Cancer Cell."},{"key":"1041_CR3","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 6, a018713\u2013a018713 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1041_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-134440","volume":"136","author":"E Bachy","year":"2020","unstructured":"Bachy, E. et al. Final analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood 136, 32\u201333 (2020).","journal-title":"Blood"},{"key":"1041_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673\u2013691 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1041_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1042\/BST20130010","volume":"41","author":"RDW Kelly","year":"2013","unstructured":"Kelly, R. D. W. & Cowley, S. M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem. Soc. Trans. 41, 741\u2013749 (2013).","journal-title":"Biochem. Soc. Trans."},{"key":"1041_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tips.2016.12.006","volume":"38","author":"CJ Millard","year":"2017","unstructured":"Millard, C. J., Watson, P. J., Fairall, L., Schwabe, J. W. R. & Targeting Class, I. Histone deacetylases in a \u2018complex\u2019 environment. Trends Pharmacol. Sci. 38, 363\u2013377 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"1041_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.272.5260.408","volume":"272","author":"J Taunton","year":"1996","unstructured":"Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase related to the yeast transciptional regulator Rpd3p. Science 272, 408\u2013411 (1996).","journal-title":"Science"},{"key":"1041_CR9","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. 6, a026831 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1041_CR10","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1073\/pnas.1000478107","volume":"107","author":"OM Dovey","year":"2010","unstructured":"Dovey, O. M., Foster, C. T. & Cowley, S. M. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc. Natl Acad. Sci. USA 107, 8242\u20138247 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1041_CR11","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","volume":"21","author":"G Lagger","year":"2002","unstructured":"Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672\u20132681 (2002).","journal-title":"EMBO J."},{"key":"1041_CR12","doi-asserted-by":"publisher","first-page":"9840","DOI":"10.1073\/pnas.1321330111","volume":"111","author":"S Jamaladdin","year":"2014","unstructured":"Jamaladdin, S. et al. Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells. Proc. Natl Acad. Sci. USA 111, 9840\u20139845 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1041_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1101\/gad.552310","volume":"24","author":"T Yamaguchi","year":"2010","unstructured":"Yamaguchi, T. et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 24, 455\u2013469 (2010).","journal-title":"Genes Dev."},{"key":"1041_CR14","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/emboj.2010.136","volume":"29","author":"RH Wilting","year":"2010","unstructured":"Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29, 2586\u20132597 (2010).","journal-title":"EMBO J."},{"key":"1041_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.devcel.2010.10.015","volume":"19","author":"M LeBoeuf","year":"2010","unstructured":"LeBoeuf, M. et al. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev. Cell 19, 807\u2013818 (2010).","journal-title":"Dev. Cell"},{"key":"1041_CR16","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2012-08-450916","volume":"121","author":"MR Heideman","year":"2013","unstructured":"Heideman, M. R. et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 121, 2038\u20132050 (2013).","journal-title":"Blood"},{"key":"1041_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood-2012-07-441949","volume":"121","author":"OM Dovey","year":"2013","unstructured":"Dovey, O. M. et al. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 121, 1335\u20131344 (2013).","journal-title":"Blood"},{"key":"1041_CR18","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2015-03-632984","volume":"126","author":"GM Matthews","year":"2015","unstructured":"Matthews, G. M. et al. Functional\u2013genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126, 2392\u20132403 (2015).","journal-title":"Blood"},{"key":"1041_CR19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","volume":"21","author":"MC Stubbs","year":"2015","unstructured":"Stubbs, M. C. et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin. Cancer Res. 21, 2348\u20132358 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1041_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.chembiol.2013.03.020","volume":"20","author":"SM Frumm","year":"2013","unstructured":"Frumm, S. M. et al. Selective HDAC1\/HDAC2 inhibitors induce neuroblastoma differentiation. Chem. Biol. 20, 713\u2013725 (2013).","journal-title":"Chem. Biol."},{"key":"1041_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-021-00967-z","volume":"53","author":"T Ito","year":"2021","unstructured":"Ito, T. et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat. Genet. 53, 1664\u20131672 (2021).","journal-title":"Nat. Genet."},{"key":"1041_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41587-020-0600-6","volume":"39","author":"PC DeWeirdt","year":"2021","unstructured":"DeWeirdt, P. C. et al. Optimization of AsCas12a for combinatorial genetic screens in human cells. Nat. Biotechnol. 39, 94\u2013104 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1041_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug Discov. 19, 23\u201338 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1041_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"1041_CR25","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1073\/pnas.1316793111","volume":"111","author":"GR Hoffman","year":"2014","unstructured":"Hoffman, G. R. et al. Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. USA 111, 3128\u20133133 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1041_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/MCB.01372-13","volume":"34","author":"BG Wilson","year":"2014","unstructured":"Wilson, B. G. et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell. Biol. 34, 1136\u20131144 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"1041_CR27","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","volume":"73","author":"T Oike","year":"2013","unstructured":"Oike, T. et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73, 5508\u20135518 (2013).","journal-title":"Cancer Res."},{"key":"1041_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","volume":"6","author":"H Ogiwara","year":"2016","unstructured":"Ogiwara, H. et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 6, 430\u2013445 (2016).","journal-title":"Cancer Discov."},{"key":"1041_CR29","doi-asserted-by":"publisher","first-page":"e26980","DOI":"10.7554\/eLife.26980","volume":"6","author":"P Lelij","year":"2017","unstructured":"Lelij, P. et al. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. eLife 6, e26980 (2017).","journal-title":"eLife"},{"key":"1041_CR30","doi-asserted-by":"publisher","first-page":"109597","DOI":"10.1016\/j.celrep.2021.109597","volume":"36","author":"PCR Parrish","year":"2021","unstructured":"Parrish, P. C. R. et al. Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome. Cell Rep. 36, 109597 (2021).","journal-title":"Cell Rep."},{"key":"1041_CR31","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1158\/2159-8290.CD-20-1213","volume":"11","author":"CF Malone","year":"2021","unstructured":"Malone, C. F. et al. Selective modulation of a pan-essential protein as a therapeutic strategy in cancer. Cancer Discov. 11, 2282\u20132299 (2021).","journal-title":"Cancer Discov."},{"key":"1041_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 (2017).","journal-title":"Cell"},{"key":"1041_CR33","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"1041_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ng0693-187","volume":"4","author":"H Caron","year":"1993","unstructured":"Caron, H. et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N\u2013myc amplification. Nat. Genet. 4, 187\u2013190 (1993).","journal-title":"Nat. Genet."},{"key":"1041_CR35","first-page":"4664","volume":"55","author":"JM Maris","year":"1995","unstructured":"Maris, J. M. et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 55, 4664\u20134669 (1995).","journal-title":"Cancer Res."},{"key":"1041_CR36","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/sj.onc.1207784","volume":"23","author":"I Janoueix-Lerosey","year":"2004","unstructured":"Janoueix-Lerosey, I. et al. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene 23, 5912\u20135922 (2004).","journal-title":"Oncogene"},{"key":"1041_CR37","first-page":"419","volume":"2","author":"RJ Komotar","year":"2008","unstructured":"Komotar, R. J., Otten, M. L., Starke, R. M. & Anderson, R. C. E. Chromosome 1p and 11q deletions and outcome in neuroblastoma\u2014a critical review. Clin. Med Oncol. 2, 419\u2013420 (2008).","journal-title":"Clin. Med Oncol."},{"key":"1041_CR38","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood.V91.9.3397","volume":"91","author":"M Merup","year":"1998","unstructured":"Merup, M. et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphomas. Blood 91, 3397\u20133400 (1998).","journal-title":"Blood"},{"key":"1041_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/10428190701817282","volume":"49","author":"EF Thelander","year":"2008","unstructured":"Thelander, E. F. et al. Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk. Lymphoma 49, 477\u2013487 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"1041_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cancergencyto.2005.06.025","volume":"165","author":"M Taborelli","year":"2006","unstructured":"Taborelli, M. et al. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 165, 106\u2013113 (2006).","journal-title":"Cancer Genet Cytogenet"},{"key":"1041_CR41","doi-asserted-by":"crossref","unstructured":"Aktas Samur, A. et al. Deciphering the chronology of copy number alterations in multiple myeloma. Blood Cancer J. 9, 39 (2019).","DOI":"10.1038\/s41408-019-0199-3"},{"key":"1041_CR42","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin, A. D. et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat. Genet. 50, 1240\u20131246 (2018).","journal-title":"Nat. Genet."},{"key":"1041_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41588-018-0044-9","volume":"50","author":"R Zeid","year":"2018","unstructured":"Zeid, R. et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat. Genet. 50, 515\u2013523 (2018).","journal-title":"Nat. Genet."},{"key":"1041_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","volume":"53","author":"NV Dharia","year":"2021","unstructured":"Dharia, N. V. et al. A first-generation pediatric cancer dependency map. Nat. Genet. 53, 529\u2013538 (2021).","journal-title":"Nat. Genet."},{"key":"1041_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1172\/JCI90793","volume":"128","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. CRISPR\u2013Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J. Clin. Invest. 128, 446\u2013462 (2018).","journal-title":"J. Clin. Invest."},{"key":"1041_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"1041_CR47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.celrep.2019.12.048","volume":"30","author":"J Garc\u00eda-L\u00f3pez","year":"2020","unstructured":"Garc\u00eda-L\u00f3pez, J. et al. Large 1p36 deletions affecting Arid1a locus facilitate mycn-driven oncogenesis in neuroblastoma. Cell Rep. 30, 454\u2013464 (2020).","journal-title":"Cell Rep."},{"key":"1041_CR48","doi-asserted-by":"crossref","unstructured":"Shi H., et al. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv. 6, eaaz3440 (2020).","DOI":"10.1126\/sciadv.aaz3440"},{"key":"1041_CR49","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1041_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature21688","volume":"543","author":"MA Erb","year":"2017","unstructured":"Erb, M. A. et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543, 270\u2013274 (2017).","journal-title":"Nature"},{"key":"1041_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","volume":"14","author":"B Nabet","year":"2018","unstructured":"Nabet, B. et al. The dTAG system for immediate and target-specific protein degradation. Nat. Chem. Biol. 14, 431\u2013441 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1041_CR52","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.molcel.2021.02.015","volume":"81","author":"MG Jaeger","year":"2021","unstructured":"Jaeger, M. G. & Winter, G. E. Fast-acting chemical tools to delineate causality in transcriptional control. Mol. Cell 81, 1617\u20131630 (2021).","journal-title":"Mol. Cell"},{"key":"1041_CR53","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.crchbi.2021.100011","volume":"1","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. & Erb, M. A. Enabling cancer target validation with genetically encoded systems for ligand-induced protein degradation. Curr. Res Chem. Biol. 1, 100011 (2021).","journal-title":"Curr. Res Chem. Biol."},{"key":"1041_CR54","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/nprot.2018.015","volume":"13","author":"PJ Skene","year":"2018","unstructured":"Skene, P. J., Henikoff, J. G. & Henikoff, S. Targeted in situ genome-wide profiling with high efficiency for low cell numbers. Nat. Protoc. 13, 1006\u20131019 (2018).","journal-title":"Nat. Protoc."},{"key":"1041_CR55","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nmeth.4435","volume":"14","author":"VA Herzog","year":"2017","unstructured":"Herzog, V. A. et al. Thiol-linked alkylation of RNA to assess expression dynamics. Nat. Methods 14, 1198\u20131204 (2017).","journal-title":"Nat. Methods"},{"key":"1041_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0153767","volume":"11","author":"JR Shearstone","year":"2016","unstructured":"Shearstone, J. R. et al. Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2. PLoS ONE 11, 1\u201327 (2016).","journal-title":"PLoS ONE"},{"key":"1041_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"1041_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nbt.3130","volume":"33","author":"C Sch\u00f6lz","year":"2015","unstructured":"Sch\u00f6lz, C. et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat. Biotechnol. 33, 415\u2013425 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1041_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.54993","volume":"9","author":"JG Marques","year":"2020","unstructured":"Marques, J. G. et al. NURD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. eLife 9, 1\u201330 (2020).","journal-title":"eLife"},{"key":"1041_CR60","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41588-019-0534-4","volume":"51","author":"BE Gryder","year":"2019","unstructured":"Gryder, B. E. et al. Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma. Nat. Genet. 51, 1714\u20131722 (2019).","journal-title":"Nat. Genet."},{"key":"1041_CR61","doi-asserted-by":"publisher","first-page":"eaap9752","DOI":"10.1126\/scisignal.aap9752","volume":"11","author":"KB Emdal","year":"2018","unstructured":"Emdal, K. B. et al. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Sci. Signal 11, eaap9752 (2018).","journal-title":"Sci. Signal"},{"key":"1041_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12935-015-0224-y","volume":"15","author":"A Rihani","year":"2015","unstructured":"Rihani, A., Vandesompele, J., Speleman, F. & Van Maerken, T. Inhibition of CDK4\/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int. 15, 76 (2015).","journal-title":"Cancer Cell Int."},{"key":"1041_CR63","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.chembiol.2021.07.002","volume":"28","author":"Y Xiong","year":"2021","unstructured":"Xiong, Y. et al. Chemo-proteomics exploration of HDAC degradability by small molecule degraders. Cell Chem. Biol. 28, 1514\u20131527 (2021).","journal-title":"Cell Chem. Biol."},{"key":"1041_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","volume":"27","author":"JHR Hsu","year":"2020","unstructured":"Hsu, J. H. R. et al. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell Chem. Biol. 27, 41\u201346 (2020).","journal-title":"Cell Chem. Biol."},{"key":"1041_CR65","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","volume":"15","author":"W Farnaby","year":"2019","unstructured":"Farnaby, W. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 672\u2013680 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1041_CR66","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41588-021-00777-3","volume":"53","author":"S Schick","year":"2021","unstructured":"Schick, S. et al. Acute BAF perturbation causes immediate changes in chromatin accessibility. Nat. Genet. 53, 269\u2013278 (2021).","journal-title":"Nat. Genet."},{"key":"1041_CR67","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41588-019-0453-4","volume":"51","author":"F Sher","year":"2019","unstructured":"Sher, F. et al. Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nat. Genet. 51, 1149\u20131159 (2019).","journal-title":"Nat. Genet."},{"key":"1041_CR68","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.cell.2020.07.001","volume":"182","author":"EV Vinogradova","year":"2020","unstructured":"Vinogradova, E. V. et al. An activity-guided map of electrophile-cysteine interactions in primary human T cells. Cell 182, 1009\u20131026 (2020).","journal-title":"Cell"},{"key":"1041_CR69","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1038\/sj.onc.1210611","volume":"26","author":"SA Denslow","year":"2007","unstructured":"Denslow, S. A. & Wade, P. A. The human Mi-2\/NuRD complex and gene regulation. Oncogene 26, 5433\u20135438 (2007).","journal-title":"Oncogene"},{"key":"1041_CR70","doi-asserted-by":"publisher","first-page":"108450","DOI":"10.1016\/j.celrep.2020.108450","volume":"33","author":"JKK Low","year":"2020","unstructured":"Low, J. K. K. et al. The nucleosome remodeling and deacetylase complex has an asymmetric, dynamic, and modular architecture. Cell Rep. 33, 108450 (2020).","journal-title":"Cell Rep."},{"key":"1041_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.13941","volume":"5","author":"CJ Millard","year":"2016","unstructured":"Millard, C. J. et al. The structure of the core NuRD repression complex provides insights into its interaction with chromatin. eLife 5, 1\u201321 (2016).","journal-title":"eLife"},{"key":"1041_CR72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tibs.2022.06.002","volume":"48","author":"XJ Reid","year":"2023","unstructured":"Reid, X. J., Low, J. K. K. & Mackay, J. P. A NuRD for all seasons. Trends Biochem. Sci. 48, 11\u201325 (2023).","journal-title":"Trends Biochem. Sci."},{"key":"1041_CR73","first-page":"21.29.1","volume":"2015","author":"JD Buenrostro","year":"2015","unstructured":"Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr. Protoc. Mol. Biol. 2015, 21.29.1\u201321.29.9 (2015).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"1041_CR74","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1038\/s41467-019-11046-7","volume":"10","author":"BE Gryder","year":"2019","unstructured":"Gryder, B. E. et al. Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nat. Commun. 10, 3004 (2019).","journal-title":"Nat. Commun."},{"key":"1041_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","volume":"32","author":"K Qu","year":"2017","unstructured":"Qu, K. et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell 32, 27\u201341 (2017).","journal-title":"Cancer Cell"},{"key":"1041_CR76","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cels.2018.04.011","volume":"6","author":"J Pan","year":"2018","unstructured":"Pan, J. et al. Interrogation of mammalian protein complex structure, function, and membership using genome-scale fitness screens. Cell Syst. 6, 555\u2013568 (2018).","journal-title":"Cell Syst."},{"key":"1041_CR77","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41556-018-0221-1","volume":"20","author":"BC Michel","year":"2018","unstructured":"Michel, B. C. et al. A non-canonical SWI\/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat. Cell Biol. 20, 1410\u20131420 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1041_CR78","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrc3091","volume":"11","author":"AY Lai","year":"2011","unstructured":"Lai, A. Y. & Wade, P. A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 11, 588\u2013596 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1041_CR79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molcel.2018.06.003","volume":"71","author":"S Bornel\u00f6v","year":"2018","unstructured":"Bornel\u00f6v, S. et al. The nucleosome remodeling and deacetylation complex modulates chromatin structure at sites of active transcription to fine-tune gene expression. Mol. Cell 71, 56\u201372 (2018).","journal-title":"Mol. Cell"},{"key":"1041_CR80","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1021\/acs.jmedchem.1c02179","volume":"65","author":"JP Smalley","year":"2022","unstructured":"Smalley, J. P. et al. Optimization of class I histone deacetylase PROTACs reveals that HDAC1\/2 degradation is critical to induce apoptosis and cell arrest in cancer cells. J. Med. Chem. 65, 5642\u20135659 (2022).","journal-title":"J. Med. Chem."},{"key":"1041_CR81","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1039\/D0CC01485K","volume":"56","author":"JP Smalley","year":"2020","unstructured":"Smalley, J. P. et al. PROTAC-mediated degradation of class i histone deacetylase enzymes in corepressor complexes. Chem. Commun. 56, 4476\u20134479 (2020).","journal-title":"Chem. Commun."},{"key":"1041_CR82","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1039\/D2MD00199C","volume":"13","author":"JM Cross","year":"2022","unstructured":"Cross, J. M. et al. A \u2018click\u2019 chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. RSC Med Chem. 13, 1634\u20131639 (2022).","journal-title":"RSC Med Chem."},{"key":"1041_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1021\/acs.biochem.2c00288","volume":"62","author":"IM Baker","year":"2022","unstructured":"Baker, I. M., Smalley, J. P., Sabat, K. A., Hodgkinson, J. T. & Cowley, S. M. Comprehensive transcriptomic analysis of novel class I HDAC proteolysis targeting chimeras (PROTACs). Biochemistry 62, 645\u2013656 (2022).","journal-title":"Biochemistry"},{"key":"1041_CR84","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.chembiol.2021.03.007","volume":"28","author":"NS Scholes","year":"2021","unstructured":"Scholes, N. S., Mayor-Ruiz, C. & Winter, G. E. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches. Cell Chem. Biol. 28, 1048\u20131060 (2021).","journal-title":"Cell Chem. Biol."},{"key":"1041_CR85","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1002\/anie.201611281","volume":"56","author":"D Remillard","year":"2017","unstructured":"Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew. Chem. Int. Ed. 56, 5738\u20135743 (2017).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1041_CR86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson, C. M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14, 163\u2013170 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1041_CR87","doi-asserted-by":"crossref","unstructured":"Cantley, J. et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 13, 6814 (2022).","DOI":"10.1038\/s41467-022-34562-5"},{"key":"1041_CR88","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1021\/acs.jmedchem.2c00397","volume":"65","author":"A Gopalsamy","year":"2022","unstructured":"Gopalsamy, A. Selectivity through targeted protein degradation (TPD). J. Med. Chem. 65, 8113\u20138126 (2022).","journal-title":"J. Med. Chem."},{"key":"1041_CR89","doi-asserted-by":"crossref","unstructured":"Toriki, E. S. et al. Rational chemical design of molecular glue degraders. Cent. Sci. 9, 915\u2013926 (ACS, 2023).","DOI":"10.1021\/acscentsci.2c01317"},{"key":"1041_CR90","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nprot.2015.140","volume":"11","author":"T Sakuma","year":"2016","unstructured":"Sakuma, T., Nakade, S., Sakane, Y., Suzuki, K. I. T. & Yamamoto, T. MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat. Protoc. 11, 118\u2013133 (2016).","journal-title":"Nat. Protoc."},{"key":"1041_CR91","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nbt.3235","volume":"33","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Discovery of cancer drug targets by CRISPR\u2013Cas9 screening of protein domains. Nat. Biotechnol. 33, 661\u2013667 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1041_CR92","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1041_CR93","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & Van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1041_CR94","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12859-019-2849-7","volume":"20","author":"T Neumann","year":"2019","unstructured":"Neumann, T. et al. Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets. BMC Bioinf. 20, 258 (2019).","journal-title":"BMC Bioinf."},{"key":"1041_CR95","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nmeth.4396","volume":"14","author":"MR Corces","year":"2017","unstructured":"Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959\u2013962 (2017).","journal-title":"Nat. Methods"},{"key":"1041_CR96","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis:na knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1041_CR97","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."}],"container-title":["Nature Structural &amp; Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41594-023-01041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-023-01041-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-023-01041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:04:35Z","timestamp":1692630275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-023-01041-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1038\/s41594-023-01041-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.30.493851","asserted-by":"object"}]},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}